Triple therapy for chronic hepatitis C: Practical Aspects

Close metadata

Recommended articles:

Effectiveness and safety of different methods of removal of medium —sized benign colorectal polyps using cold snare polypectomy. Endoscopic Surgery. 2024;(4):29-36

Safety profile of pressurized intraperitoneal aerosol chemotherapy in the treatment of ovarian cancer. P.A. Herzen Journal of Oncology. 2024;(5):25-30

Proton pump inhibitors: positive and negative properties. On the 45th anniversary of their discovery. Russian Journal of Preventive Medicine. 2024;(11):135-140

The paper considers the practical aspects of antiviral therapy with protease inhibitors, a new group of antiviral agents, by using the clinical cases of treatment in patients with chronic hepatitis C as an example. It gives the general points of triple therapy, including indications for its use in previously untreated and unresponsive patients, and discusses in detail possible adverse events and ways of their prevention and correction.

Keywords:

chronic hepatitis C

antiviral therapy

protease inhibitors

telaprevir

boceprevir

adverse events

Authors:

Bakulin I.G.

I.I. Mechnikov North-Western State Medical University, Sankt-Petersburg, Russia

SPIN RSCI: 5283-2032
Scopus AuthorID: 6603812937
ResearcherID: P-4453-2014
ORCID: 0000-0002-6151-2021

Kiseleva A.V.

European Medical Centre. Moscow, Russia

List of references:

Perz J., Armstrong G., Farrington L. The contribution of hepatitis B virus and hepatitis C virus infection to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavir in compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
Desmond C.P., Roberts S.K., Dudley F. al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13: 311-315.
Sherman M., Shafran S., Burak K. et al. Management of chronic hepatitis C: consensus guedlines in hepatitis C patients. Can J Gastrienterol 2007; 21 (Suppl.): 25-34.
Hadziyannis S.J., Sette H. Jr., Morgan T.R. et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
Lopatkina T.N. Individualizirovannaya protivovirusnaya terapiya khronicheskogo gepatita S segodnya. Gepatol forum 2011; 4: 15-20.
Jacobson I., Mchutchison J., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
Sherman K., Flamm S., Afdhal N. et al. Response- guided teleprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
Zeuzem S., Andreane P., Pol S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
Syutkin V.E. Ingibitory proteazy: novyi shag na puti k personalizatsii lecheniya khronicheskogo gepatita S, vyzvannogo virusom 1 genotipa. Klin farmakol i ter 2012; 1: 11-16.
Poordad F., Mccone J., Bacon B. et al. Boceprevir for antreated chronic HCV genotipe 1 infection. N Engl J Med 2011; 364: 1195-1206.
Bacon B., Gordon S., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotip 1 infection. N Engl J Med 2011; 364: 1207-1217.
Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-651.
Poynard T., Marcellin P., Lee S. et al. Randomized trial of Interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
Veldt B., Heathcote E., Wedemeyer H. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
Morgan T., Ghany M., Kim H. et al. Sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
Maylin S., Martinot-Peignoux M., Moucari R. et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829.
Marcellin P., Boyer N.,Gervais A. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 1997; 127: 875-881.
Cardoso A.C., Moucari R., Figueirdo-Mendes C. et al. Impact of dence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
Bruno S., Stroffolini T., Colombo M. Sustained virological response to interferon is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
Sarrazin C., Kiefer T., Bartels D. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterolog 2007; 132: 1767-1777.
Kuntzen T., Timm J., Berical A. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment naive patients. Hepatology 2008; 48: 1769-1778.
Hezode C., Forestier N., Dusheiko G. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
Burnevich E.Z. Novaya paradigma individualizirovannoi protivovirusnoi terapii khronicheskogo gepatita S. Chast' 1. Botseprevir v kombinatsii s pegilirovannym interferonom al'fa i ribavirinom. Gepatol forum 2011; 4: 21-32.
Sulkowski M., Wasserman R., Brooks L. et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infectoin. J Viral Hepat 2004; 11: 243-250.
Martin L.M., Younossi Z.M., Price L.L. et al. The impact of ribavirin-induced anemia on health-related quality of life. 56th annual meeting of the American Association for the Study of Liver Diseases; November 11-15, Abstract 600.
Sulkowski M. S., Shiffman M.L., Afdhal N.H. et al. Hepatitis C virus treatment-related anemia is associated wish higher sustained virologic response rate. Gastroenterology 2010; 139: 1602-1611.
Lai M.Y., Kao J.H., Yang P.M. et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
Bakulin I.G., Sandler Yu.G., Sharabanov A.S. Gematologicheskie nezhelatel'nye yavleniya pri provedenii protivovirusnoi terapii u bol'nykh s khronicheskim gepatitom S. Gepatol forum 2011; 4: 2-14.
Nomura H., Tanimoto H., Kajivara E. et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-1317.
Dieterich D.T., Spivak J.L. Hematologik disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541.

Close metadata